GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » Additional Paid-In Capital

Kadmon Holdings (Kadmon Holdings) Additional Paid-In Capital : $505.25 Mil(As of Sep. 2021)


View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings Additional Paid-In Capital?


Kadmon Holdings's quarterly additional paid-in capital increased from Mar. 2021 ($487.23 Mil) to Jun. 2021 ($491.72 Mil) and increased from Jun. 2021 ($491.72 Mil) to Sep. 2021 ($505.25 Mil).

Kadmon Holdings's annual additional paid-in capital increased from Dec. 2018 ($315.71 Mil) to Dec. 2019 ($456.21 Mil) and increased from Dec. 2019 ($456.21 Mil) to Dec. 2020 ($515.43 Mil).


Kadmon Holdings Additional Paid-In Capital Historical Data

The historical data trend for Kadmon Holdings's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings Additional Paid-In Capital Chart

Kadmon Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Additional Paid-In Capital
Get a 7-Day Free Trial 92.17 198.86 315.71 456.21 515.43

Kadmon Holdings Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 512.90 515.43 487.23 491.72 505.25

Kadmon Holdings Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kadmon Holdings Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadmon Holdings (Kadmon Holdings) Business Description

Traded in Other Exchanges
N/A
Address
450 East 29th Street, New York, NY, USA, 10016
Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.
Executives
Harlan Waksal director, officer: President, CEO WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer director C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris director 103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan officer: Executive Vice President, CMO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan officer: EVP, Chief Financial Officer 450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver officer: Principal Accounting Officer, Controller 450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss officer: EVP, General Counsel, Chief Compliance Officer 450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc other: Former 10% owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon officer: Exec VP, GC, Chief Admin, Comp C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016

Kadmon Holdings (Kadmon Holdings) Headlines

From GuruFocus

Kadmon to Present at Upcoming Investor Conferences

By ACCESSWIRE ACCESSWIRE 05-26-2021